Phase 2 Trial of PRM-151, an Anti-Fibrotic Agent, in Patients with Myelofibrosis:
Stage 1 Results

Verstovsek R, et al. American Society of Clinical Oncology (ASCO) 2014 Annual Meeting, June 2014.

[click to download pdf]